Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Molecular Epidemiology and Transmission Dynamics of Recent and Long-Term HIV-1 Infections in Rural Western Kenya.

Zeh C, Inzaule SC, Ondoa P, Nafisa LG, Kasembeli A, Otieno F, Vandenhoudt H, Amornkul PN, Mills LA, Nkengasong JN.

PLoS One. 2016 Feb 12;11(2):e0147436. doi: 10.1371/journal.pone.0147436. eCollection 2016.

2.

HIV Testing and Diagnosis Rates in Kiev, Ukraine: April 2013-March 2014.

Simmons R, Malyuta R, Chentsova N, Medoeva A, Kruglov Y, Yurchenko A, Copas A, Porter K; CASCADE Collaboration in EuroCoord.

PLoS One. 2015 Aug 31;10(8):e0137062. doi: 10.1371/journal.pone.0137062. eCollection 2015.

3.

Creating an African HIV clinical research and prevention trials network: HIV prevalence, incidence and transmission.

Kamali A, Price MA, Lakhi S, Karita E, Inambao M, Sanders EJ, Anzala O, Latka MH, Bekker LG, Kaleebu P, Asiki G, Ssetaala A, Ruzagira E, Allen S, Farmer P, Hunter E, Mutua G, Makkan H, Tichacek A, Brill IK, Fast P, Stevens G, Chetty P, Amornkul PN, Gilmour J; IAVI Africa HIV Prevention Partnership.

PLoS One. 2015 Jan 20;10(1):e0116100. doi: 10.1371/journal.pone.0116100. eCollection 2015.

4.

Host genetics and viral load in primary HIV-1 infection: clear evidence for gene by sex interactions.

Li X, Price MA, He D, Kamali A, Karita E, Lakhi S, Sanders EJ, Anzala O, Amornkul PN, Allen S, Hunter E, Kaslow RA, Gilmour J, Tang J; IAVI Africa HIV Prevention Partnership.

Hum Genet. 2014 Sep;133(9):1187-97. doi: 10.1007/s00439-014-1465-x. Epub 2014 Jun 27.

5.

Evaluation of rapid progressors in HIV infection as an extreme phenotype.

Olson AD, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, Lodi S, Ghosn J, Dorrucci M, Johnson A, Sannes M, Moreno S, Porter K; for CASCADE Collaboration in EuroCoord.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):15-21. doi: 10.1097/QAI.0000000000000240.

6.

An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration.

Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord.

PLoS One. 2014 Jan 28;9(1):e86719. doi: 10.1371/journal.pone.0086719. eCollection 2014.

7.

Dynamics of viremia in primary HIV-1 infection in Africans: insights from analyses of host and viral correlates.

Prentice HA, Price MA, Porter TR, Cormier E, Mugavero MJ, Kamali A, Karita E, Lakhi S, Sanders EJ, Anzala O, Amornkul PN, Allen S, Hunter E, Kaslow RA, Gilmour J, Tang J; IAVI Africa HIV Prevention Partnership.

Virology. 2014 Jan 20;449:254-62. doi: 10.1016/j.virol.2013.11.024. Epub 2013 Dec 12.

8.

Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection.

Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Vanhems P, Boufassa F, Guiguet M, Porter K; CASCADE Collaboration in EuroCoord.

PLoS One. 2013 Nov 14;8(11):e78642. doi: 10.1371/journal.pone.0078642. eCollection 2013.

9.

Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa.

Amornkul PN, Karita E, Kamali A, Rida WN, Sanders EJ, Lakhi S, Price MA, Kilembe W, Cormier E, Anzala O, Latka MH, Bekker LG, Allen SA, Gilmour J, Fast PE; IAVI Africa HIV Prevention Partnership.

AIDS. 2013 Nov 13;27(17):2775-86. doi: 10.1097/QAD.0000000000000012.

10.

Natural history of HIV-control since seroconversion.

Madec Y, Boufassa F, Porter K, Prins M, Sabin C, d'Arminio Monforte A, Amornkul P, Bartmeyer B, Sannes M, Venet A, Lambotte O, Meyer L; CASCADE Collaboration in Eurocoord.

AIDS. 2013 Sep 24;27(15):2451-60. doi: 10.1097/01.aids.0000431945.72365.01.

PMID:
23912979
11.

High percentage of recent HIV infection leading to onward transmission in Odessa, Ukraine associated with young adults.

Simmons R, Semenenko I, Tolpina M, Tereschenko R, Kotlik L, Zasyptka L, Murphy G, McKinney E, Copas A, Malyuta R, Porter K; CASCADE collaboration in EuroCoord.

AIDS Behav. 2014 Feb;18(2):411-8. doi: 10.1007/s10461-013-0518-9.

PMID:
23686153
12.

HLA-B*57 versus HLA-B*81 in HIV-1 infection: slow and steady wins the race?

Prentice HA, Porter TR, Price MA, Cormier E, He D, Farmer PK, Kamali A, Karita E, Lakhi S, Sanders EJ, Anzala O, Amornkul PN, Allen S, Hunter E, Kaslow RA, Gilmour J, Tang J; IAVI African HIV Research Network.

J Virol. 2013 Apr;87(7):4043-51. doi: 10.1128/JVI.03302-12. Epub 2013 Jan 30.

13.

High percentage of recent HIV infection among HIV-positive individuals newly diagnosed at voluntary counseling and testing sites in Poland.

Rosińska M, Marzec-Bogustawska A, Janiec J, Smoleń-Dzirba J, Wąsik T, Gniewosz J, Zalewska M, Murphy G, McKinney E, Porter K; CASCADE Collaboration In Eurocoord.

AIDS Res Hum Retroviruses. 2013 May;29(5):805-13. doi: 10.1089/AID.2012.0314. Epub 2013 Feb 26.

14.

Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997.

van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Chêne G, Dorrucci M, Muga R, Porter K, Prins M; CASCADE Collaboration in EuroCoord.

Gastroenterology. 2013 Apr;144(4):751-760.e2. doi: 10.1053/j.gastro.2012.12.026. Epub 2012 Dec 22.

PMID:
23266560
15.

Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts.

Touloumi G, Pantazis N, Pillay D, Paraskevis D, Chaix ML, Bucher HC, Kücherer C, Zangerle R, Kran AM, Porter K; CASCADE collaboration in EuroCoord.

Clin Infect Dis. 2013 Mar;56(6):888-97. doi: 10.1093/cid/cis1000. Epub 2012 Dec 7.

PMID:
23223594
16.

Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts.

Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, Wu H, Johnson AM; Beijing PRIMO cohort study; CASCADE Collaboration in EuroCoord.

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):441-6. doi: 10.1097/QAI.0b013e31827f5c9a.

PMID:
23221982
17.

Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones.

Baalwa J, Wang S, Parrish NF, Decker JM, Keele BF, Learn GH, Yue L, Ruzagira E, Ssemwanga D, Kamali A, Amornkul PN, Price MA, Kappes JC, Karita E, Kaleebu P, Sanders E, Gilmour J, Allen S, Hunter E, Montefiori DC, Haynes BF, Cormier E, Hahn BH, Shaw GM.

Virology. 2013 Feb 5;436(1):33-48. doi: 10.1016/j.virol.2012.10.009. Epub 2012 Nov 1.

18.

Risk of tuberculosis following HIV seroconversion in high-income countries.

Lodi S, del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E; CASCADE collaboration in EuroCoord.

Thorax. 2013 Mar;68(3):207-13. doi: 10.1136/thoraxjnl-2012-201740. Epub 2012 Oct 31.

19.

Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection.

Zugna D, Geskus RB, De Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix ML, Babiker A, Porter K; CASCADE Collaboration in EuroCoord.

Antivir Ther. 2012;17(6):1039-48. doi: 10.3851/IMP2312. Epub 2012 Aug 15.

PMID:
22910338
20.

Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.

Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G; CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group.

PLoS One. 2012;7(3):e32369. doi: 10.1371/journal.pone.0032369. Epub 2012 Mar 6.

Supplemental Content

Loading ...
Support Center